# Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110E

> **NCT01813487** · NA · COMPLETED · sponsor: **Genexine, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** HBsAg vaccine with Entecavir

## Key facts

- **NCT ID:** NCT01813487
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2013-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01813487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01813487, "Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110E". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01813487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*